Loading...
Management of myelofibrosis after ruxolitinib failure
Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. Constitutive activation of the Janus kinase/signal transducer...
Na minha lista:
| Udgivet i: | Ann Hematol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Berlin Heidelberg
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7237516/ https://ncbi.nlm.nih.gov/pubmed/32198525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-020-04002-9 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|